A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 3, 2012, Pages 432-440

  Kirschbaum, Mark H ^a   Stein, Anthony S ^a   Popplewell, Leslie ^a   Delioukina, Maria ^a   Chen, Robert ^a   Nakamura, Ryotaro ^a   Snyder, David ^a   Conrad, Joel ^a   Lacey, Simon F ^b   Frankel, Paul ^a   Dagis, Andrew ^a   Nademanee, Auayporn ^a   Forman, Stephen J ^a  

^a City of Hope ^*  (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Immune reconstitution; Leukemia; Purine analog

Indexed keywords

CLOFARABINE; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLADDER DISEASE; CANCER MORTALITY; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENGRAFTMENT; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HUMAN CELL; KIDNEY DISEASE; LEUKEMIA RELAPSE; LUNG DISEASE; MALE; MORTALITY; NEUTROPHIL COUNT; PHASE 1 CLINICAL TRIAL; REDUCED INTENSITY CONDITIONING; STOMATITIS; STROKE; THROMBOCYTE FUNCTION; TOXIC HEPATITIS; TREATMENT OUTCOME;

ADENINE NUCLEOTIDES; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MELPHALAN; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84856955527     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.07.017     Document Type: Article

References (35)

1. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001, 344:175-181.
2. Michallet M., Thomas X., Vernant J.P., et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced-stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffede Moelle (SFGM). Bone Marrow Transplant 2000, 26:1157-1163.
3. Suciu S., Mandelli F., de Witte T., et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003, 102:1232-1240.
4. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979, 300:1068-1073.
5. Sullivan K.M., Weiden P.L., Storb R., et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989, 73:1720-1728.
6. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
7. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005, 105:1810-1814.
8. Sayer H.G., Kroger M., Beyer J., et al. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003, 31:1089-1095.
9. Bertz H., Potthoff K., Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003, 21:1480-1484.
10. Deeg H.J., Shulman H.M., Anderson J.E., et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 2000, 95:1188-1194.
11. King K.M., Damaraju V.L., Vickers M.F., et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol 2006, 69:346-353.
12. Genini D., Adachi S., Chao Q., et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000, 96:3537-3543.
13. Carson D.A., Wasson D.B., Esparza L.M., et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine. Proc Natl Acad Sci USA 1992, 89:2970-2974.
14. Carson D.A., Wasson D.B., Taetle R., et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983, 62:737-743.
15. Rodriguez R., Nakamura R., Palmer J.M., et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010, 115:1098-1105.
16. Bearman S.I., Appelbaum F.R., Buckner C.D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988, 6:1562-1568.
17. Gooley T.A., Martin P.J., Fisher L.D., et al. Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation. Control Clin Trials 1994, 15:450-462.
18. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000, 96:4075-4083.
19. Valcarcel D., Martino R., Sureda A., et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005, 74:144-151.
20. Kantarjian H.M., Gandhi V., Kozuch P., et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003, 21:1167-1173.
21. Kantarjian H.M., Erba H.P., Claxton D., et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. JClin Oncol 2010, 28:549-555.
22. Burnett A.K., Russell N.H., Kell J., et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. JClin Oncol 2010, 28:2389-2395.
23. Andersson B.S., Valdez B.C., de Lima M., et al. Clofarabine ± fludarabine with once-daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011, 17:893-900.
24. Storek J., Geddes M., Khan F., et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol 2008, 30:425-437.
25. Seggewiss R., Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010, 115:3861-3868.
26. Klyuchnikov E., Asenova S., Kern W., et al. Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia. Leuk Lymphoma 2010, 51:1450-1463.
27. Maris M., Boeckh M., Storer B., et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003, 31:941-952.
28. Petersen S.L., Ryder L.P., Bjork P., et al. A comparison of T-, B- and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen-identical sibling donors. Bone Marrow Transplant 2003, 32:65-72.
29. Busca A., Lovisone E., Aliberti S., et al. Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation. Hematology 2003, 8:303-311.
30. Morecki S., Gelfand Y., Nagler A., et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low-intensity vs myeloablative regimen. Bone Marrow Transplant 2001, 28:243-249.
31. Jimenez M., Ercilla G., Martinez C. Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens. Leukemia 2007, 21:1628-1637.
32. Jimenez M., Martinez C., Ercilla G., et al. Reduced-intensity conditioning regimen preserves thymic function in the early period after hematopoietic stem cell transplantation. Exp Hematol 2005, 33:1240-1248.
33. Schulenburg A., Fischer M., Kalhs P., et al. Immune recovery after conventional and non-myeloablative allogeneic stem cell transplantation. Leuk Lymphoma 2005, 46:1755-1760.
34. Chao N.J., Liu C.X., Rooney B., et al. Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells. Biol Blood Marrow Transplant 2002, 8:249-256.
35. Saito T., Kanda Y., Nakai K., et al. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation. Bone Marrow Transplant 2003, 32:601-608.